AXGN:NASDAQ
AxoGen, Inc Common Stock
55,40ย US$
0,00%
(0,00) 1 d
56,18ย US$
arrow_upward
+1,41% (+0,78)todayFรถre รถppningen
Stรคngd: 12 nov., 16:00:01 GMTโ5 · USD
search
Alla symboler
| Symbol | Pris | รndring | รndring i procent |
|---|
insights_autoGenererar de viktigaste insikterna fรถr AXGNย โฆ
Bรถrsvรคrde
3,31ย md
Genomsn. vol.
1,98ย mn
Volym
624,00
52v hรถgst
59,72ย US$
52v lรคgst
23,00ย US$
EPS
โ0,68ย US$
Beta
1,21
Utestรฅende aktier
59,73ย mn
Antal anstรคllda
622
Bรถrsvรคrde
3,31ย md
Genomsn. vol.
1,98ย mn
Volym
624,00
52v hรถgst
59,72ย US$
52v lรคgst
23,00ย US$
EPS
โ0,68ย US$
Beta
1,21
Utestรฅende aktier
59,73ย mn
Antal anstรคllda
622
Nyheter och artiklar
Frรฅn webbkรคllor och nyhetspartner
Zacks
·
fรถr 21 timmar sedan
AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Investing.com
·
fรถr 1 dag sedan
Axogen stock hits 52-week high at $52.92
Investing.com
·
fรถr 1 dag sedan
AxoGen at Canaccord forum: growth plan widens beyond nerve repair
Profil
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Om AxoGen, Inc Common Stock
Vd-
Anstรคllda622
Grundades2002
HuvudkontorAlachua, Florida, USA
SektorHealth Care
Bransch-
Webbplatsaxogeninc.com